Results 61 to 70 of about 182,500 (270)

A Case of Pembrolizumab-Induced Myasthenia Gravis

open access: yes, 2023
With the advent of new cancer treatments, immunotherapy has emerged as an increasingly promising strategy. Undoubtedly, it has pushed oncology into a new era and is providing patients with unprecedented results.
Dada, Bolanle   +3 more
core   +3 more sources

Pembrolizumab promotes degradation of cyclin dependent kinase 6 and suppresses ovarian cancer progression in vitro

open access: yesScientific Reports
Pembrolizumab is a novel humanized anti-PD-1 monoclonal antibody capable of enhancing T-cell mediated antitumor immunity. However, the function of pembrolizumab on tumor cells themselves and relative molecular mechanism in ovarian cancer remain unknown ...
Yi Wu   +5 more
doaj   +1 more source

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

open access: yesAdvanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang   +6 more
wiley   +1 more source

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2021
Lili Wu, Bixun Li Department of Integrated Medicine, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of ChinaCorrespondence: Bixun LiDepartment of Integrated Medicine, Guangxi Medical University Cancer ...
Wu L, Li B
doaj  

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis

open access: yesFrontiers in Oncology, 2022
BackgroundPembrolizumab and cemiplimab have been approved as treatment for advanced non-small-cell lung cancer (NSCLC) with high programmed death ligand-1 (PD-L1) expression.
Yan Li   +5 more
doaj   +1 more source

Renal toxicities associated with pembrolizumab

open access: yes, 2019
International audienceObjective : Expanded clinical experience with patients treated by pembrolizumab has accumulated. However, renal toxicities associated with this anti-programmed cell death 1 agent are poorly described because kidney histology is ...
Michels, Judith   +18 more
core   +1 more source

AL398, A Novel NSUN6 Inhibitor, Attenuates Epithelial‐Mesenchymal Transition and Metastasis in Endometrial Cancer by Abrogating m5C‐Dependent Stabilization of Snail mRNA

open access: yesAdvanced Science, EarlyView.
Proposed molecular mechanism: NSUN6 catalyzes m5C methylation on Snail mRNA to enhance its stability, leading to Snail upregulation and EMT promotion. The first‐in‐class inhibitor AL398 suppresses endometrial cancer metastasis by targeting the NSUN6‐m5C‐Snail. axis. ABSTRACT Endometrial cancer (EC) constitutes a leading gynecologic malignancy for which
Xiangzhuan Zhao   +19 more
wiley   +1 more source

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation

open access: yesAdvanced Science, EarlyView.
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai   +7 more
wiley   +1 more source

Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: A case report

open access: yesUrology Case Reports, 2019
A case of fulminant type 1 diabetes mellitus secondary to administration of pembrolizumab in a patient with urothelial carcinoma is presented. Eight days after the third infusion of pembrolizumab, the patient presented with complaints of malaise and ...
Yoichiro Tohi   +5 more
doaj   +1 more source

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

open access: yes, 2022
Purpose: This prespecified exploratory analysis evaluated the association between tumor mutational burden (TMB) status and outcomes of first-line pembrolizumab±chemotherapy versus chemotherapy in KEYNOTE-062.
정현철
core   +1 more source

Home - About - Disclaimer - Privacy